SCHEMBL2660012

SCHEMBL2660012

CCCN1Cc2nc3c(-c4ccccc4Cl)cccc3c(N)c2C1=O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.38
▸ PARP1 P09874 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ PARP2 Q9UGN5 1/20 0.38
▸ ACHE P22303 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPK10 P53779 1/20 0.35
▸ PDE5A O76074 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ APOBEC3G Q9HC16 1/20 0.35
▸ TLR8 Q9NR97 1/20 0.34
▸ DPP4 P27487 1/20 0.33
▸ DPP8 Q6V1X1 1/20 0.33
▸ CHEK1 O14757 1/20 0.32
▸ WEE1 P30291 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2660719 0.90 CRHR1 (0.36) LMNAPARP1HTTPARP2ALDH1A1
SCHEMBL2660780 0.88 GABRG2 (0.42) LMNAPARP1HTTPARP2ALDH1A1
SCHEMBL2660713 0.87 HRH4 (0.42) LMNAPARP1HTTPARP2ALDH1A1
SCHEMBL4921477 0.87 LMNA (0.36) LMNAPARP1HTTPARP2ACHE
SCHEMBL2660762 0.86 HTT (0.35) LMNAPARP1HTTPARP2ALDH1A1
SCHEMBL2655502 0.86 HTT (0.35) LMNAPARP1HTTPARP2ALDH1A1
SCHEMBL4915502 0.86 LMNA (0.36) LMNAPARP1HTTPARP2ALDH1A1
SCHEMBL2655382 0.85 LMNA (0.38) LMNAPARP1HTTPARP2ALDH1A1
SCHEMBL2661809 0.85 TLR8 (0.37) LMNAPARP1HTTPARP2ALDH1A1
SCHEMBL2661216 0.85 DPP4 (0.36) LMNAPARP1HTTPARP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF LMNA 1909/4885PARP1 1350/4885HTT 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback